I. AMENDMENTS TO THE CLAIMS

Claim 1-6. (Canceled)

Claim 7. (New) A process for obtaining high purity polyvinylacetates, comprising the steps of:

(1) polymerizing vinyl acetate in a solution, wherein dibenzoyl peroxide is used as an initiator, and wherein the solution comprises alcohol;

(2) purifying by:

- adding a volume of water to said solution;
- heating or maintaining the temperature of the resulting mixture to > 80°C;
- mechanically stirring the mixture;
- optionally passing purified air through the mixture while maintaining the temperature of the mixture at 80°C to 100° C;
- separating from the mixture a semi-solid polymer mass;
- heating said polymer mass at a temperature between 80°C and 140°C in a vacuum of 0.02 – 13 kPa; and
- stirring said polymer mass until the polymer presents the desired purity and dryness; and

(3) taking the purified polymer mass from the purification equipment.

Claim 8. (New) A process of claim 7, wherein the solution of step (1) comprises ethanol or a volatile alcohol.

Claim 9. (New) A process of claim 7, wherein the volume of water added to said solution in step (2) has a temperature of > 80°C.

Claim 10. (New) Polyvinylacetates obtained by the process of claim 7, wherein the polyvinylacetates have:

(1) mean molecular weight between 10,000 and 40,000 Daltons;

(2) remnant monomer content of less than 2 ppm by weight;

(3) water content less than 1.5% by weight;

(4) total acidity referred to acetic acid less than 0.5% by weight;
(5) peroxide content of 0.0%; and
(6) glass transition temperature of 35°C to 39°C

Claim 11. (New) A method of producing solid pharmaceutical preparations, comprising using the polyvinylacetates of claim 10 as a binder, alone or in combination with other binders, in base granulates or granulates that contain an active substance, wherein the polyvinylacetates are used in a solution with solvent or as a solid powder.

Claim 12. (New) A method of producing solid pharmaceutical preparations, comprising using the polyvinylacetates of claim 10 as a binder and the sole or main constituents of release controlling matrices, wherein the content of the polyvinylacetates is higher than 60 weight % in the controlling release matrices and is between 2-25 weight % of the solid pharmaceutical preparation.